Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

We assessed the long-term efficacy of imatinib dose escalation in 84 patients with chronic myeloid leukemia in chronic phase who met the criteria of failure to standard-dose imatinib. Twenty-one patients with hematologic failure and 63 with cytogenetic failure had their imatinib dose escalated from...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jabbour, Elias, Kantarjian, Hagop M., Jones, Dan, Shan, Jenny, O'Brien, Susan, Reddy, Neeli, Wierda, William G., Faderl, Stefan, Garcia-Manero, Guillermo, Verstovsek, Srdan, Rios, Mary Beth, Cortes, Jorge
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2009
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081392/
https://ncbi.nlm.nih.gov/pubmed/19060245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-04-154344
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky